| Certification: | GMP |
|---|---|
| Grade Standard: | Medicine Grade |
| Type: | API |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Lincomycin hydrochloride Lincomycin hydrochloride displays as a pristine white crystalline powder at room temperature, carrying a slight or distinct aroma and a bitter taste. This remarkable compound is soluble in both water and methanol. Commonly utilized in its hydrochloride salt form, this drug is a byproduct of the growth of the Streptomyces genus (Streptomyces lincolnensis) and stands as a potent member of the lincosamide class of alkaline antibiotics.
| Basic Information | |
| Product name | Lincomycin Hydrochloride |
| Grade | Pharmaceutical Grade |
| Appearance | White crystal powder |
| Assay | 99% |
| Shelf life | 3 Years |
| Packing | 25kg/drum |
| Condition | stored in a cool and dry place |
Primarily, it is employed in combating infections provoked by Gram-positive bacteria, especially those resistant to penicillin. Lincomycin hydrochloride is also effective in treating poultry respiratory diseases instigated by Mycoplasma, swine enzootic pneumonia, and anaerobic infections including chicken necrotizing enterocolitis.
Additionally, it aids in the treatment of treponema dysentery, toxoplasmosis, and actinomycosis in dogs and cats, broadening its application across various species.
Lincomycin is a member of the lincosamide antibiotic family, derived from the actinomyces Streptomyces lincolnensis. A closely related antibiotic, clindamycin, is formulated from lincomycin by substituting the 7-hydroxy group with an atom, accompanied by a chirality inversion.
Though structurally akin to macrolides, and sharing a similar antibacterial spectrum and mechanism of action, lincomycin is also potent against organisms such as actinomycetes, mycoplasma, and certain Plasmodium species. Administering a single intramuscular dose of 600 mg results in average peak serum levels of 11.6 micrograms/ml within an hour, sustaining therapeutic levels for 17 to 20 hours against most susceptible Gram-positive bacteria. Urinary excretion after this dose varies between 1.8 to 24.8 percent, with an average of 17.3 percent.
1. Oral formulations are ideally suited for addressing respiratory infections, abdominal infections, infections of the female reproductive tract, pelvic infections, as well as skin and soft tissue infections induced by sensitive strains such as Staphylococcus aureus and Streptococcus pneumoniae.
2. Beyond treating the aforementioned infections, injected formulations are recommended for severe infections caused by streptococcus, pneumococcus, and staphylococcus. These include surgical adjuvant therapy for septicemia, bone and joint infections, chronic bone and joint infections, and acute hematogenous osteomyelitis induced by Staphylococcus.
3. Lincomycin hydrochloride serves as an alternative treatment for infectious diseases in patients who are allergic to penicillin or unsuitable for penicillin-type medications.
){kind=link}